Clinical Trial Update: Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine [Phase 3]

View source ↗

Summary

A Phase 3 immunogenicity and safety study evaluating a booster dose of GSK's Poliorix (IPV) and Infanrix+Hib (DTPa/Hib) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Tetanus

Drugs mentioned

• Infanrix/Hib
• Poliorix (inactivated poliovirus vaccine (IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2017-04-13